Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free SVA Stock Alerts

Sernova (SVA) Competitors

Sernova logo
C$0.12 +0.01 (+9.09%)
As of 07/22/2026 03:59 PM Eastern
Compare

SVA vs. IPA, SCYB, COM, NVH, and HBP

Should you buy Sernova stock or one of its competitors? MarketBeat compares Sernova with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sernova include ImmunoPrecise Antibodies (IPA), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), and Helix BioPharma (HBP). These companies are all part of the "biotechnology" industry.

How does Sernova compare to ImmunoPrecise Antibodies?

Sernova (TSE:SVA) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

ImmunoPrecise Antibodies has higher revenue and earnings than Sernova. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SernovaN/AN/A-C$35.70M-C$0.04N/A
ImmunoPrecise AntibodiesC$19.47M8.33-C$22.19M-C$0.89N/A

In the previous week, Sernova had 1 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 1 mentions for Sernova and 0 mentions for ImmunoPrecise Antibodies. Sernova's average media sentiment score of 0.00 equaled ImmunoPrecise Antibodies'average media sentiment score.

Company Overall Sentiment
Sernova Neutral
ImmunoPrecise Antibodies Neutral

Sernova's return on equity of 55.85% beat ImmunoPrecise Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
SernovaN/A 55.85% -119.26%
ImmunoPrecise Antibodies N/A N/A N/A

0.0% of Sernova shares are owned by institutional investors. 12.1% of Sernova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Sernova beats ImmunoPrecise Antibodies on 6 of the 9 factors compared between the two stocks.

How does Sernova compare to Scythian Biosciences?

Sernova (TSE:SVA) and Scythian Biosciences (CVE:SCYB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

In the previous week, Sernova had 1 more articles in the media than Scythian Biosciences. MarketBeat recorded 1 mentions for Sernova and 0 mentions for Scythian Biosciences. Sernova's average media sentiment score of 0.00 equaled Scythian Biosciences'average media sentiment score.

Company Overall Sentiment
Sernova Neutral
Scythian Biosciences Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SernovaN/AN/A-C$35.70M-C$0.04N/A
Scythian BiosciencesN/AN/AN/AN/AN/A

Sernova's return on equity of 55.85% beat Scythian Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
SernovaN/A 55.85% -119.26%
Scythian Biosciences N/A N/A N/A

0.0% of Sernova shares are owned by institutional investors. 12.1% of Sernova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Sernova beats Scythian Biosciences on 4 of the 5 factors compared between the two stocks.

How does Sernova compare to 138267 (COM.TO)?

138267 (COM.TO) (TSE:COM) and Sernova (TSE:SVA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

In the previous week, Sernova had 1 more articles in the media than 138267 (COM.TO). MarketBeat recorded 1 mentions for Sernova and 0 mentions for 138267 (COM.TO). 138267 (COM.TO)'s average media sentiment score of 0.00 equaled Sernova'saverage media sentiment score.

Company Overall Sentiment
138267 (COM.TO) Neutral
Sernova Neutral

Sernova's return on equity of 55.85% beat 138267 (COM.TO)'s return on equity.

Company Net Margins Return on Equity Return on Assets
138267 (COM.TO)N/A N/A N/A
Sernova N/A 55.85%-119.26%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
138267 (COM.TO)N/AN/AN/AN/AN/A
SernovaN/AN/A-C$35.70M-C$0.04N/A

0.0% of Sernova shares are owned by institutional investors. 12.1% of Sernova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Sernova beats 138267 (COM.TO) on 4 of the 5 factors compared between the two stocks.

How does Sernova compare to Novoheart?

Novoheart (CVE:NVH) and Sernova (TSE:SVA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

0.0% of Sernova shares are owned by institutional investors. 12.1% of Sernova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Novoheart has higher revenue and earnings than Sernova. Novoheart is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A
SernovaN/AN/A-C$35.70M-C$0.04N/A

In the previous week, Sernova had 1 more articles in the media than Novoheart. MarketBeat recorded 1 mentions for Sernova and 0 mentions for Novoheart. Novoheart's average media sentiment score of 0.00 equaled Sernova'saverage media sentiment score.

Company Overall Sentiment
Novoheart Neutral
Sernova Neutral

Sernova's return on equity of 55.85% beat Novoheart's return on equity.

Company Net Margins Return on Equity Return on Assets
NovoheartN/A N/A N/A
Sernova N/A 55.85%-119.26%

Summary

Sernova beats Novoheart on 5 of the 9 factors compared between the two stocks.

How does Sernova compare to Helix BioPharma?

Sernova (TSE:SVA) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

0.0% of Sernova shares are held by institutional investors. Comparatively, 0.0% of Helix BioPharma shares are held by institutional investors. 12.1% of Sernova shares are held by company insiders. Comparatively, 2.2% of Helix BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Sernova has a beta of -0.449346, suggesting that its stock price is 145% less volatile than the broader market. Comparatively, Helix BioPharma has a beta of 0.431088, suggesting that its stock price is 57% less volatile than the broader market.

Sernova's return on equity of 55.85% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
SernovaN/A 55.85% -119.26%
Helix BioPharma N/A -21.54%-279.98%

Helix BioPharma is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SernovaN/AN/A-C$35.70M-C$0.04N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

In the previous week, Sernova and Sernova both had 1 articles in the media. Helix BioPharma's average media sentiment score of 0.75 beat Sernova's score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sernova
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Helix BioPharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Sernova beats Helix BioPharma on 6 of the 8 factors compared between the two stocks.

Get Sernova News Delivered to You Automatically

Sign up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SVA vs. The Competition

Export
MetricSernovaBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$41.54MC$528.46MC$7.01BC$13.01B
Dividend Yield7.86%3.90%2.67%6.19%
P/E Ratio-3.003.4926.8836.99
Price / SalesN/A6,282.29574.129.63
Price / Cash6.1513.1350.6082.29
Price / Book-4.3787.6810.564.48
Net Income-C$35.70M-C$96.07MC$3.60BC$299.09M
7 Day Performance9.09%-0.12%-1.35%1.24%
1 Month Performance-17.24%-0.48%-0.30%0.86%
1 Year Performance-31.43%56.41%18.98%30.94%

Sernova Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SVA
Sernova
N/AC$0.12
+9.1%		N/A-31.4%C$41.54MN/AN/A1,959
IPA
ImmunoPrecise Antibodies
N/AC$6.50
+0.8%		N/A+0.0%C$162.08MC$19.47MN/A80
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/A+0.0%C$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A
NVH
Novoheart
N/AC$0.53
+1.9%		N/A+0.0%C$99.98MC$423.50KN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:SVA) was last updated on 7/23/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel